1. Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells
   Ali Hosseini Rad S. M. et al, 2021, Cancers CrossRef
2. Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy
   Yasmin Jenkins et al, 2021, Antibodies CrossRef
3. PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report
   Chenggong Li et al, 2021, Front. Immunol. CrossRef
4. Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications
   Ding-Kang Wang et al, 2021, Front. Immunol. CrossRef
5. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
   Moritz Ernst et al, 2021 CrossRef
6. Improving CAR T-Cell Persistence
   Violena Pietrobon et al, 2021, IJMS CrossRef
7. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis
   Irit Avivi et al, 2022, Ann Hematol CrossRef
8. Molecular Aspects of Resistance to Immunotherapies—Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma
   Aleksandra Kusowska et al, 2022, IJMS CrossRef
9. CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response
   Oscar Cienfuegos-Jimenez et al, 2022, CGT CrossRef
10. IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
    Huihui Zhang et al, 2022, Human Vaccines & Immunotherapeutics CrossRef
11. Cytokine release syndrome after CAR T-cell therapy: a review of the literature and our experience
    B Čemusová, 2022, Anest. intenziv. Med. CrossRef
12. Monitoraggio delle complicanze da tossicità nei pazienti sottoposti a CAR-T: studio osservazionale, prospettico
    Francesca Palmisano et al, 2022, Work Paper Public Hlth CrossRef
13. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
    Leo I. Gordon et al, 2023, Oncotarget CrossRef
14. IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma
    Sheridan L. Swan et al, 2023, Front. Immunol. CrossRef
15. Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis
    Sabine Seidel et al, 2023, Neurol. Res. Pract. CrossRef
16. Efficacy and Safety of Dual-Targeting Chimeric Antigen Receptor-T Therapy for Relapsed or Refractory B Cell Lymphoid Malignancies: A Systematic Review and Meta-Analysis
    Min Yu et al, 2023, Human Gene Therapy CrossRef
17. Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor‐T cell therapy
    Cecilia C. S. Yeung et al, 2024, European J of Haematology CrossRef
18. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels
    Ying Li et al, 2024, Front. Immunol. CrossRef